CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism","$":{"href":"/biotech/roche-pens-25b-pact-hanmis-clinical-stage-obesity-drug-targeting-less-used-mechanism","hreflang":"en"}}]}

PartnershipPositive
AI Analysis

Summary

Roche entered into a $2.5 billion licensing agreement with Hanmi Pharm for a clinical-stage urocortin-2 analog targeting obesity, with a $190 million upfront payment.

Importance:7/10
Sentiment:
0.70
obesitylicensing dealclinical stageurocortin-2RocheHanmi
Related Companies

Read the original article

Published by FierceBiotech on August 24, 2026 4:44 AM

Read Original